Nabil Gharios
Fondatore presso Healthcare Promise Investment Partners SA
Provenienza dei contatti di primo grado di Nabil Gharios
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Perinvest (UK) Ltd.
Perinvest (UK) Ltd. Investment ManagersFinance Perinvest (UK) Ltd. is the alternative investment management subsidiary of Perinvest Holdings Ltd. in Great Britain. The firm was founded by Jean R. Perrette in 2001. Headquartered in London with an additional office in Bermuda, Perinvest UK manages a diversified family of sub-funds within the Perinvest (Lux) SICAV UCITS umbrella for institutions, trusts and high net-worth individual clients.
5
| Subsidiary | Investment Managers | 5 |
Biotech Promise
1
| Private Company | Miscellaneous | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Nabil Gharios tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
ABBOTT LABORATORIES | Medical Specialties | Corporate Officer/Principal | |
SMITH & NEPHEW PLC | Medical Specialties | Chief Executive Officer | |
SHIRE | Pharmaceuticals: Major | Director/Board Member | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
RECKITT BENCKISER GROUP PLC | Household/Personal Care | Director/Board Member | |
SMITHS GROUP PLC | Electrical Products | Director/Board Member | |
TAKEDA PHARMACEUTICAL COMPANY LIMITED | Pharmaceuticals: Major | Director/Board Member | |
VIRBAC | Biotechnology | Director/Board Member | |
Pierre Fabre SA
Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France. | Pharmaceuticals: Major | Chief Executive Officer | |
European American Securities, Inc.
European American Securities, Inc. Investment Banks/BrokersFinance Part of European American Perinvest Group Ltd., European American Securities, Inc. is a British company that provides security brokerage services. The company is based in London, UK. | Investment Banks/Brokers | President | |
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Chairman | |
Essex Woodlands Management, Inc.
Essex Woodlands Management, Inc. Investment ManagersFinance Essex Woodlands Management, Inc. (EW Healthcare Partners) is a private equity firm founded in 1985 by Jim L. Currie and Martin P. Sutter. The firm is headquartered in Houston, Texas. | Investment Managers | Consultant / Advisor | |
University of Paris Jussieu | College/University | Doctorate Degree | |
École des Hautes Études Commerciales de Paris | College/University | Masters Business Admin | |
CIM Investment Management Ltd.
CIM Investment Management Ltd. Investment ManagersFinance CIM Investment Management Ltd. (CIM) is an independent alternative investment management firm headquartered in London, UK. The firm was founded in 2005 by James Morton. CIM provides portfolio-based investment management services on a discretionary and non-discretionary basis to high net-worth individuals, family offices, trusts, and institutions. | Investment Managers | Compliance Officer Chief Investment Officer | |
Académie des Technologies
Académie des Technologies Academie des Technologies engages in the technology industry. The company was founded in December 2000 and is headquartered in Paris, France. | Corporate Officer/Principal | ||
Abbott Pharmaceutical, Inc. | President | ||
Laboratoires Majorelle SAS
Laboratoires Majorelle SAS Medical DistributorsDistribution Services Laboratoires Majorelle SAS operates as an independent French pharmaceutical company. Its products include Vitaros, Optilov, Keat range, and Carmex. The company was founded by Guillaume El Glaoui in 2012 and is headquartered in Paris, France. | Medical Distributors | Chairman | |
Académie nationale de Pharmacie | Corporate Officer/Principal | ||
Smith & Nephew A/S (Denmark)
Smith & Nephew A/S (Denmark) Medical SpecialtiesHealth Technology Smith & Nephew A/S operates as a is a global medical technology business. It specializes in healthcare, medical supplies, medical devices, wound care, orthopaedic reconstruction and sports medicine. The company was founded by Thomas James Smith in 1856 and is headquartered in Horsholm, Denmark. | Medical Specialties | Chief Executive Officer | |
OJB Conseil SAS | Chairman | ||
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | Medical Specialties | Founder | |
Biotech Promise SCA SICAV-SIF | Director/Board Member | ||
Majorelle Topco Ltd. | Director/Board Member |
Statistiche
Distribuzione geografica
Francia | 11 |
Regno Unito | 8 |
Stati Uniti | 4 |
Danimarca | 3 |
Irlanda | 2 |
Settori
Health Technology | 12 |
Finance | 4 |
Consumer Services | 3 |
Consumer Non-Durables | 2 |
Producer Manufacturing | 2 |
Posizioni
Director/Board Member | 12 |
Chief Executive Officer | 5 |
Corporate Officer/Principal | 4 |
Chairman | 4 |
Independent Dir/Board Member | 3 |
Contatti più connessi
- Borsa valori
- Insiders
- Nabil Gharios
- Connessioni Società